Skip to main content

Advertisement

Figure 4 | Cancer Cell International

Figure 4

From: Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model

Figure 4

Administration of SF1126 decreased the baseline levels of phospho-ERK and EGF-induced activation of ERK in the glioma cells from12 V-Ha-Ras transgenic mice. A. Left panel shows effect of SF1126 on the levels of phospho-ERK in the glioma cells from 12 V-Ha-Ras transgenic mice. Derivative glioma cells grown in 10% serum conditions were treated with two different concentrations (25 μM and 50 μM) of SF1126. Right panel shows that treatment of LY294002 (50 μM) and PD98059 (20 μM) blocked the activation of ERK in the derivative glioma cells. B. Effect of SF1126 on EGF-stimulated levels of phospho-ERK in the derivative glioma cells from 12 V-Ha-Ras transgenic mice. Glioma cells cultured in serum free media were stimulated with EGF (100 ng/ml) and treated with 25 μM and 50 μM of SF1126. Experiments were repeated three times with similar results.

Back to article page